Case Presentation: Hirsutism and Oligomenorrhea
Case Presentation: Hirsutism and Oligomenorrhea
Case Presentation: Hirsutism and Oligomenorrhea
History
menarche at 10, 3-4 menstrual cycle/year since than, last period: 3 months ago Her father has diabetes mellitus type II Her mother is hypertensive, obese (BMI= 33 kg/m2)
She had low birth weight with rapid catch-up growth, No chronic medication use, no recent stress or ilness, No change in weight, diet or strenous exercise
age of onset 11, slow rate of progression Tanner Stage 5, (B5, PH5) Ferriman Gallwey score 14, Acne vulgaris, seborrhea, hyperhidrosis,
Physical:
BMI= 23 kg/m2.( H=162 cm, W=60,5 kg) Blood presure=110/70 mmHg Waist/hip ratio= 0,80
Physical examination
Ferriman-Gallwey score Scores above 8 suggest an excess of androgen-mediated hair growth that should be confirmed by hormonal evaluation.
Lab studies
Kariotype 46,XX; PRL = 23 ng/ml , (Normal range <20 ng/ml) LH = 21 IU/ml , (Normal range 5- 20 IU/ml) FSH = 9 IU/ml , (Normal range 6- 16 IU/ml) Testosteorone (total) = 1,2 ng/mL
17-hydroxiprogesteronum = 4 nmol/L
Lab studies
SHBG=0.85 g/dl
Lab studies
TSH=2,31 IU/ml FT4= 0,98 ng/ml cholesterol = 223 mg/dL; LDL cholesterol = 152 mg/dL, HDL cholesterol = 39 mg/dl TG = 160 mg/dl Fastig plasma glucose = 93 mg/dl 2 h plasma glucose (OGTT)=131 mg/dl
Imaging study
10-20 mg/day of dydrogesterone or 5 mg/day of MPA for 10 days. The presence of withdrawal bleeding within 7 days after treatment indicates that:
the outflow tract is intact, sufficient estrogen was present at the outset to stimulate endometrial growth.
Diagnosis
Differential diagnosis
Treatment - options
1.
2.
3. 4. 5.
Oral contraceptive pill (OCP) Progestin alone Metformin 2x 850 mg/day Spironolactone 2x 100mg/day Cyproterone acetate
in combination with estradiol in Diane 35 or as Androcur 25-100 mg in the first 10 days of OCP GnRH agonist therapy Finasteride, Flutamide
6.
Other:
Lifestyle modification
impaired glucose tolerance (or type 2 DM), increased risk of cardiovascular disease, nonalcoholic steatohepatitis (NASH) obstructive sleep apnea, development of endometrial adenocarcinoma, infertility.